Ixocal 3% is single treatment. viscoelastic gel injectable prefilled syringe used intra articular for treating arthritis it is similar to synovial fluid. a substance that occurs naturally in the joints. synovial fluid acts as a lubricant and shock absorber.
Welcome to IXOCAL, where we provide innovative solutions for joint health. Our mission is to improve the quality of life for individuals with joint conditions through advanced medical treatments.
Ixocal 3% is natural cross-linked hyaluronate 90mg/3ml solution of highly purified sodium hyaluronate with high molecular weight (4.5 million Daltons).
Obtained by bio fermentative process, synthetic origin gives a complete safety elimination any allergic reactions.
Ixocal 3% is a prefilled syringe having aluminum blister for sealing that assures 3 years guarantee of validity, sterilized by autoclave.
Treatment: 1 injection
90mg/3ml (3%) sodium hyaluronate
Average molecular weight 4.5 million Daltons (viscometric data).
Elasticity minimum 10 pa (2.5 maximum effort).
Viscosity minimum 45 pa (2.5 Hz, maximum effort).
Hyaluronic acid with Ixocal 3% in the treatment of degenerative joint disease.
Hyaluronan contributes to the synovial fluid's lubricating properties and also controls fluid flow into and out the joint space.
Hyaluronic acid (HA) acts as a mediator of the inflammatory response.
Ixocal 3% improved by cross linking, preponderantly elastic, confers capacity mechanic protection increased and improved lubrication (45 pa characteristic human synovial fluid)
Is indicated for the symptomatic treatment of mild to severe osteoarthritis.
Ixocal 3% is recommended for patients that have joint pain coupled with reduced mobility. These symptoms can occur as a result of degenerative disease or trauma.
Ixocal 3% treats pain and restricted mobility and elasticity, protects cartilage as a result of traumatic pathology in knee joint and other synovial joints (hip, ankle, shoulder, elbow, wrist, fingers, toes, and the temporomandibular and facet joints).
Is also indicated for the reduction of post-arthroscopy pain. Is contraindicated in children, pregnant or breast-feeding women.
Ixocal 3% is produced according to good manufacturing practice (GMP) and ISO 13485 being certified as a system with high quality ingredients, CE marked device being in accordance with the European directive 93/42/EE.